Background {#Sec1}
==========

Coronary artery disease (CAD) is projected to become the dominant cause of death and disability worldwide by 2020 \[[@CR1]\]. Although reduction of traditional risk factors for CAD is associated with 30 to 40% less adverse events such as death and myocardial infarction (MI) \[[@CR2]\], residual cardiovascular risk is a challenge due to the genetic predisposition \[[@CR3]--[@CR8]\]. In recent years, some significant progress has been made in identifying genes that are associated with susceptibility to the development of CAD/MI. However, there has been remarkable lack of replication, and difficulty in identifying genes that underlie impressive linkage peaks due to the heterogeneities of phenotype and their associations with genotype. We present two first-degree family members of acute myocardial infarction (AMI) with clinical and angiographic similarities.

Case presentation {#Sec2}
=================

The father, a 61-year-old man with a history of heavy smoking (30 cigarettes per day for 40 years) presented with significant chest discomfort and loss of consciousness, which returned after 5 min. His initial electrocardiogram (ECG) showed an acute anterior ST-segment--elevation myocardial infarction (STEMI; Fig. [1](#Fig1){ref-type="fig"}a). In the emergency department, the symptoms were released and partial resolution of ST-segment was noted on the ECG 1 h post-thrombolysis with reteplase. Coronary angiogram demonstrated a subtotal occlusion in the mid-left anterior descending (LAD) coronary artery (Fig. [1](#Fig1){ref-type="fig"}b and Additional file [1](#MOESM1){ref-type="media"}: Video S1) with moderate disease in the right coronary artery (Fig. [1](#Fig1){ref-type="fig"}c and Additional file [2](#MOESM2){ref-type="media"}: Video S2). He successfully underwent percutaneous coronary intervention (PCI) and stent implantation. One week later after discharge, the son presented with AMI. The 32-year-old man, also with a history of heavy smoking (40 cigarettes per day for 10 years), presented after an in-hospital cardiac arrest with pulseless electric activity (PEA) preceded by significant chest pain and loss of consciousness. Cardiopulmonary resuscitation was started for PEA arrest with return of spontaneous circulation after 3 min. His initial ECG showed an acute anterior STEMI (Fig. [1](#Fig1){ref-type="fig"}d). The emergency catheterization revealed strikingly similar angiographic characteristics with his father: subtotal occlusion in the proximal to mid-LAD coronary artery (Fig. [1](#Fig1){ref-type="fig"}e and Additional file [3](#MOESM3){ref-type="media"}: Video S3) with tubular disease in the right coronary artery (Fig. [1](#Fig1){ref-type="fig"}f and Additional file [4](#MOESM4){ref-type="media"}: Video S4). He also successfully underwent PCI and stent implantation. Interestingly, either the father or the son had no history of hypertension, diabetes mellitus, hyperlipidemia, and other cardiovascular risk factors except smoking. They had no history of any emotional or psychiatric diseases. The patients were not taking any prescription medication and had no known allergies before admission. All laboratory values of the father and son were detailed in Table [1](#Tab1){ref-type="table"}. All the members of the family were studied, which comprised only the two affected individuals (Fig. [1](#Fig1){ref-type="fig"}g). Fig. 1Patient's imaging data. **a**: The father's initial ECG demonstrating an anterior STEMI; **b**: The father's coronary angiogram demonstrating a subtotal occlusion in middle part of LAD; **c**: The father's coronary angiogram demonstrating moderate stenosis in the right coronary artery; **d**: The son's initial ECG demonstrating an anterior STEMI; **e**: The son's coronary angiogram demonstrating subtotal occlusion in the proximal to middle part of LAD; **f**: The son's coronary angiogram demonstrating tubular disease in the right coronary artery; **g**: Pedigrees of the familyTable 1Laboratory Values of the Father and SonLaboratory variablesFatherSonInitial cTnI (ng/mL)2.30.42Peak cTnI (ng/mL)\> 50\> 50Creatinine (umol/L)8645FPG (mmol/L)7.25.8LDL-C (mmol/L)1.922.54HDL-C (mmol/L)0.981.04K+ (mmol/L)4.23.9LVEDD (mm)4845LVEF (%)4653*cTnI* cardiac troponin I, *FPG* fasting plasma glucose, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* high-density lipoprotein cholesterol, *K*^*+*^ potassium ion**,***LVEDD* left ventricular end diastolic dimension, *LVEF* left ventricular ejection fraction

Discussion and conclusion {#Sec3}
=========================

Despite an extensive body of research dedicated to the genetic basis of CAD, most of the identified genes individually or in combination confer relatively small increments in risk (1.1- to 1.5-fold) and explain only a small proportion of heritability \[[@CR9]--[@CR11]\]. Also notable and insightful studies are available, some focusing on juvenile onset CAD, while others enrolled patients with maturity-onset CAD. And even though the studied subjects suffered from MI, their inclusion criteria varied considerably. Defectiveness in certain genetic clusters predispose to similar but clinical entities; some to CAD and others to MI. It is importance to draw clear distinction between clinical syndrome because the phenotype of CAD in some studies has been consistently switched with that of MI in another \[[@CR2]--[@CR16]\].

Carl Miller et al \[[@CR17]\] first described the co-segregation of elevated cholesterol, xanthomas and premature CAD, providing some clues regarding a genetic trait of CAD/MI. Clinical and population-based studies have subsequently demonstrated that genetic factors play important roles in CAD/MI \[[@CR18]--[@CR27]\]. Twin studies estimated the heritability of CAD/MI to be approximately 50 to 60% \[[@CR3]--[@CR8]\]. Understanding the genetic basis of CHD/MI will not only help to understand the pathogenesis of the disease, but also lay the foundation for the development of precise prevention and treatment strategies \[[@CR28]\].

However, scientific work at the molecular level thus the genetic architecture of CAD/MI has been formidable and ultra-expensive task owing to the heterogeneities of clinical presentation of CAD/MI and the elaborate pathophysiological processes underpinning both the genetics and the environmental factors and their interactions \[[@CR28]\]. Clinically, atherosclerotic CAD comprises a broad spectrum of clinical entities that include completely asymptomatic myocardial ischemia, angina pectoris, and acute myocardial infarction (AMI) to sudden cardiac death.

It has been recognized that hemodynamic shear forces are largely responsible for the specific sites of the vasculature, either susceptible or resistant to developing atherosclerosis. Usually the deficiency in genes or genetic mutations may have some effects on atherosclerotic lesion burden, not the distribution of plaque \[[@CR29]\]. However, the location-dependent effects of platelet endothelial cell adhesion molecule-1 (PECAM-1) on atherosclerotic lesions have been reported \[[@CR30], [@CR31]\]. The outcomes points to the different genetic influences of atherosclerosis, and their clinical heterogeneity of the location of culprit atherosclerotic lesions of CAD/MI may represent differently under different dynamic flow conditions \[[@CR32]\]. These heterogeneities of phenotypic characterization, pathological etiologies of CAD/MI and the complex molecular and cellular pathogenesis of atherosclerosis contribute to the difficulties associated with the identification of genes that are important for CAD/MI \[[@CR33]\].

Despite the clinical heterogeneity of CAD/MI as described above, the phenomenon of familial clustering of CAD/MI and collections of large pedigrees with multiple members in multiple generations provided an opportunity to perform linkage analysis and gene discovery. Careful consideration should be given to similar phenotypic characterisation of patients in genetic studies of CAD/MI in the future. On the basis of the concerns that have been reviewed, we present a rare case report of a first-degree relative of AMI with clinical and angiographic similarities.

There were limitations for this report. For example, we were unable to analyze the patients' genetic background without the consent of the patients and their family. It still gives us valuable clues in further research.

In conclusion, more considerations should be given to patients with similar phenotypic characterization in genetic studies of CAD/MI in the future. It may facilitate replication and progress in this research arena.

Supplementary information
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**Additional file 1: Video S1**. Father's left coronary angiogram. **Additional file 2: Video S2**. Father's right coronary angiogram. **Additional file 3: Video S3**. Son's left coronary angiogram. **Additional file 4: Video S4**. Son's right coronary angiogram.
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